ADO09, a co‐formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes

Aim To study safety, efficacy and weight loss with ADO09, a co‐formulation of insulin A21G and pramlintide, in type 1 diabetes. Materials and Methods A randomized, two‐arm ambulatory 16‐week study compared ADO09 with insulin lispro in 80 participants with type 1 diabetes. We compared changes of weig...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2024-10, Vol.26 (10), p.4639-4645
Hauptverfasser:	Andersen, Grit, Eloy, Rosy, Heise, Tim, Gaudier, Martin, Mégret, Claire, Seroussi, Cyril, Chan, You‐Ping, Soula, Olivier, Riddle, Matthew, DeVries, J. Hans
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Blood Glucose - drug effects Blood Glucose - metabolism Diabetes Diabetes mellitus (insulin dependent) Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - drug therapy Drug Combinations Female Glucose monitoring Glycated Hemoglobin - analysis Glycated Hemoglobin - drug effects Glycated Hemoglobin - metabolism Hemoglobin Humans Hypoglycemia Hypoglycemia - chemically induced Hypoglycemic Agents - therapeutic use Insulin Insulin - administration & dosage Insulin - analogs & derivatives Insulin - therapeutic use Insulin Lispro - administration & dosage Insulin Lispro - therapeutic use insulin therapy Islet Amyloid Polypeptide - therapeutic use Male Middle Aged phase 2 study randomized trial subcutaneous injection Treatment Outcome type 1 diabetes Weight weight control Weight Loss - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!